Kymera Therapeutics, Inc. Announces Amendment to Bylaws: New Exclusive Federal Forum Provision

Watertown, MA, March 27, 2026 – Kymera Therapeutics, Inc. (“Kymera” or the “Company”; NASDAQ: KYMR) has announced a significant amendment to its corporate bylaws, as detailed in its latest SEC Form 8-K filing.

Key Points for Investors

• Adoption of Federal Forum Selection Provision: On March 25, 2026, Kymera’s Board of Directors approved an amendment to the Company’s Second Amended and Restated Bylaws (the “Bylaw Amendment”). This amendment designates the federal district courts of the United States as the exclusive forum for resolving any complaint asserting a cause of action arising under:
  • The Securities Act of 1933, as amended
  • The Securities Exchange Act of 1934, as amended
  • Or their respective rules and regulations, unless the Company consents in writing to an alternative forum
• Response to Delaware Law Changes: This move is in direct response to recent amendments to the General Corporation Law of the State of Delaware (DGCL) regarding forum selection provisions.
• Other Forum Provisions: Unless Kymera consents in writing to an alternative forum, the Delaware Court of Chancery remains the exclusive forum for (i) derivative claims on behalf of the company, (ii) claims for breach of fiduciary duty by officers, directors, employees, or stockholders, (iii) actions arising under the DGCL or the charter or bylaws, or (iv) claims governed by the internal affairs doctrine—except for securities law actions, which now move to federal courts.
• Immediate Effectiveness: The Bylaw Amendment became effective immediately upon Board approval on March 25, 2026.
• Shareholder Impact: Any person or entity acquiring shares of Kymera stock is deemed to have notice and consented to these forum provisions to the fullest extent permitted by law.

Why This Is Important for Shareholders

• Potential Impact on Shareholder Litigation: By mandating that all Securities Act and Exchange Act claims be heard in federal district courts, Kymera is seeking to prevent costly and potentially conflicting multi-forum litigation. This can lead to more predictable and efficient resolution of shareholder claims and may reduce legal expenses for the Company—potentially benefiting shareholders.
• Corporate Governance Update: The Board’s action demonstrates proactive compliance with evolving Delaware law, and may enhance Kymera’s defense posture against certain types of lawsuits, which could be viewed positively by investors focused on governance and risk management.
• Possible Share Price Sensitivity: Changes to bylaw provisions, especially those affecting shareholder rights and litigation, can sometimes lead to increased scrutiny or volatility in the Company’s share price. Investors should be aware that these changes may impact the Company’s legal exposure and could influence market perceptions of risk.

Additional Details

• Exhibit Filed: The full text of Amendment No. 1 to the Second Amended and Restated Bylaws is attached as Exhibit 3.1 to the Form 8-K.
• Corporate Information: Kymera’s principal executive offices are located at 500 North Beacon Street, 4th Floor, Watertown, MA 02472. The Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “KYMR.”
• Signatory: The filing was signed by President and Chief Executive Officer Dr. Nello Mainolfi on March 27, 2026.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The author and publisher assume no responsibility or liability for any errors or omissions in the content of this article or for any actions taken based on this information. The information herein is based on filings made by Kymera Therapeutics, Inc. with the U.S. Securities and Exchange Commission as of March 27, 2026, and may be subject to change without notice.

View Kymera Therapeutics, Inc. Historical chart here